Category: Irritable Bowel Syndrome

Lubiprostone Overview

Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company. The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006.[1] It was recommended for use i...

Read more Lubiprostone Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Lubiprostone Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 24mcg, 24ugm, 8mcg, 8ugm
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lubiprostone: (2 results)

Sorted by National Drug Code
  • 0254-3028 Lubiprostone 8 ug/1 Oral Capsule, Gelatin Coated by Par Pharmaceutical Inc.
  • 0254-3029 Lubiprostone 24 ug/1 Oral Capsule, Gelatin Coated by Par Pharmaceutical Inc.

Other drugs which contain Lubiprostone or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 17 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA